601 related articles for article (PubMed ID: 20205482)
1. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus.
Neumiller JJ; White JR; Campbell RK
Drugs; 2010 Mar; 70(4):377-85. PubMed ID: 20205482
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitus.
Scheen AJ
Drugs; 2015 Jan; 75(1):33-59. PubMed ID: 25488697
[TBL] [Abstract][Full Text] [Related]
3. Sodium glucose co-transporter 2 inhibitors and their mechanism for improving glycemia in patients with type 2 diabetes.
Davidson JA; Kuritzky L
Postgrad Med; 2014 Oct; 126(6):33-48. PubMed ID: 25414933
[TBL] [Abstract][Full Text] [Related]
4. Targeting renal glucose reabsorption for the treatment of type 2 diabetes mellitus using the SGLT2 inhibitor dapagliflozin.
Jabbour SA; Whaley JM; Tirmenstein M; Poucher SM; Reilly TP; Boulton DW; Saye J; List JF; Parikh S
Postgrad Med; 2012 Jul; 124(4):62-73. PubMed ID: 22913895
[TBL] [Abstract][Full Text] [Related]
5. [Dapagliflozin, the first SGLT-2 inhibitor in the treatment of type 2 diabetes].
Albarrán OG; Ampudia-Blasco FJ
Med Clin (Barc); 2013 Sep; 141 Suppl 2():36-43. PubMed ID: 24444523
[TBL] [Abstract][Full Text] [Related]
6. A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
Chao EC
Discov Med; 2011 Mar; 11(58):255-63. PubMed ID: 21447284
[TBL] [Abstract][Full Text] [Related]
7. Sodium-glucose cotransporter inhibition: therapeutic potential for the treatment of type 2 diabetes mellitus.
Raskin P
Diabetes Metab Res Rev; 2013 Jul; 29(5):347-56. PubMed ID: 23463735
[TBL] [Abstract][Full Text] [Related]
8. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes.
Nauck MA
Drug Des Devel Ther; 2014; 8():1335-80. PubMed ID: 25246775
[TBL] [Abstract][Full Text] [Related]
9. Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes.
Jabbour SA; Goldstein BJ
Int J Clin Pract; 2008 Aug; 62(8):1279-84. PubMed ID: 18705823
[TBL] [Abstract][Full Text] [Related]
10. The potential role of sodium glucose co-transporter 2 inhibitors in combination therapy for type 2 diabetes mellitus.
Lajara R
Expert Opin Pharmacother; 2014 Dec; 15(17):2565-85. PubMed ID: 25316597
[TBL] [Abstract][Full Text] [Related]
11. The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.
Vallon V
Annu Rev Med; 2015; 66():255-70. PubMed ID: 25341005
[TBL] [Abstract][Full Text] [Related]
12. Dapagliflozin, an SGLT2 inhibitor for the treatment of type 2 diabetes.
Demaris KM; White JR
Drugs Today (Barc); 2013 May; 49(5):289-301. PubMed ID: 23724409
[TBL] [Abstract][Full Text] [Related]
13. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
Calado J
IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
[TBL] [Abstract][Full Text] [Related]
14. [Contributions of SGLT-2 and new drugs under investigation].
Mediavilla Bravo JJ
Semergen; 2014 Jul; 40 Suppl 2():34-40. PubMed ID: 25311718
[TBL] [Abstract][Full Text] [Related]
15. Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus.
Gerich JE; Bastien A
Expert Rev Clin Pharmacol; 2011 Nov; 4(6):669-83. PubMed ID: 22111852
[TBL] [Abstract][Full Text] [Related]
16. SGLT2-inhibitors: a novel class for the treatment of type 2 diabetes introduction of SGLT2-inhibitors in clinical practice.
Cuypers J; Mathieu C; Benhalima K
Acta Clin Belg; 2013; 68(4):287-93. PubMed ID: 24455799
[TBL] [Abstract][Full Text] [Related]
17. The role of kidney in glucose homeostasis--SGLT2 inhibitors, a new approach in diabetes treatment.
Andrianesis V; Doupis J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):519-39. PubMed ID: 23978089
[TBL] [Abstract][Full Text] [Related]
18. Clinical implication of SGLT2 inhibitors in type 2 diabetes.
Kim GW; Chung SH
Arch Pharm Res; 2014 Aug; 37(8):957-66. PubMed ID: 24950857
[TBL] [Abstract][Full Text] [Related]
19. Targeting renal glucose reabsorption to treat hyperglycaemia: the pleiotropic effects of SGLT2 inhibition.
Vallon V; Thomson SC
Diabetologia; 2017 Feb; 60(2):215-225. PubMed ID: 27878313
[TBL] [Abstract][Full Text] [Related]
20. Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug.
Idris I; Donnelly R
Diabetes Obes Metab; 2009 Feb; 11(2):79-88. PubMed ID: 19125776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
